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Abstract 
Translation of drug candidates into clinical settings requires demonstration of preclinical efficacy 
and formal toxicology analysis for filling an Investigational New Drug (IND) application with the 
US Food & Drug Administration (FDA). Here, we investigate the membrane-associated glucose 
response protein 78 (GRP78) as a therapeutic target in leukemia and lymphoma. We evaluated 
the efficacy of the GRP78-targeted pro-apoptotic drug Bone Metastasis Peptidomimetic 78 
(BMTP-78), a member of the D(KLAKLAK)2-containing class of agents. BMTP-78 was validated 
in cells from patients with acute myeloid leukemia (AML) and in a panel of human leukemia and 
lymphoma cell lines, where it induced dose-dependent cytotoxicity in all samples tested. Based 
on the in vitro efficacy of BMTP-78, we performed formal Good Laboratory Practice (GLP) 
toxicology studies in both rodents (mice and rats) and nonhuman primates (cynomolgus and 
rhesus monkeys). These analyses represent required steps towards an IND application of 
BMTP-78 for theranostic first-in-human clinical trials. 
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Introduction 
Human cancers are characterized by abnormal activation of stress-response chaperons to inhibit 
apoptosis and regulate senescence and autophagy.1 Stress-response chaperons consist in two 
families: heat-shock proteins and glucose-regulated proteins (GRP). Among the latter, GRP78 
has been widely studied as a biomarker of endoplasmic reticulum stress and an activator of the 
unfolded protein response;2 these processes have been related to drug resistance in tumor 
cells.3, 4 Unexpectedly, GRP78 has been found associated to the cell membrane in many cancer 
types, a feature that enables specific targeting by circulating ligands.5-8 In addition to our original 
discovery of cell-surface GRP78, we have recently reported that GRP78 is up-regulated and 
systemically accessible in aggressive variants of human prostate and breast cancer, and can 
thereby be exploited for theranostic purposes.9, 10 
High expression of GRP78 and its localization at the cell surface in human B-lineage acute 
lymphoblastic leukemia (ALL) is associated with disease relapse and chemotherapy 
resistance.11 GRP78-knockout mice show reduced multiplication of hematopoietic stem cells, 
loss of lymphoid and myeloid progenitors, and decreased lymphoid cell populations.5 Conditional 
knockout in the hematopoietic system indicates that GRP78 plays a mechanistic role both in 
leukemogenesis12 and in hematopoietic stem cell survival.13 In preclinical studies, GRP78 
induces AKT oncogenic signaling and leukemogenesis in PTEN-null mice,12 and its cell-surface 
association with Cripto is functional in hematopoietic stem cell quiescence.14 
In this study, we provide evidence that GRP78 accumulates on the surface of cells from 
patients with acute myeloid leukemia (AML), as well as on human leukemia and lymphoma cell 
lines, where it can serve as an accessible molecular target. As a leukemia/lymphoma-targeting 
agent, we tested Bone Metastasis Targeting Peptidomimetic 78 (BMTP-78), a prototype drug 
composed by a GRP78-binding peptide, WIFPWIQL,5, 7, 15 fused to the pro-apoptotic enantiomer 
D(KLAKLAK)2, which disrupts the mitochondrial membrane causing cell death.5, 7, 16 Previous 
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work from our group revealed that BMTP-78 inhibits tumor growth and prolongs survival in 
preclinical models of breast and prostate cancer.5, 7 Our current results indicate that BMTP-78 
exerts a dose-dependent cytotoxicity in vitro in a panel of human leukemia and lymphoma cell 
lines, as well as primary cells from patients with AML. The overall positive outcome of BMTP-78 
treatment in several preclinical models of human cancers prompted us to conduct exploratory 
Good Laboratory Practice (GLP) toxicology studies in rodents and nonhuman primates towards 
formal application of an Investigational New Drug (IND) with the US Food & Drug Administration 
(FDA). 
 
Materials and Methods 
Human leukemia and lymphoma cell lines 
The human cell lines were obtained from the Leukemia Cell and Tissue Bank of the Department 
of Leukemia at The University of Texas M.D. Anderson Cancer Center (UTMDACC). The panel 
included: MOLT-4 and CCRF-CEM (T-cell ALL), HL-60 (acute promyeolocytic leukemia), OCI-
AML3 (AML), THP-1 (monocytic acute leukemia), K562 and KBM7 (chronic myelogenous 
leukemias, CML), SR-786 (anaplastic large T-cell lymphoma), U937 and TUR (monocytic 
lymphomas), TF-1 (erythroleukemia), and RPMI-8226 (multiple myeloma). Cells were 
maintained in standard humidified hypoxia chambers (HeraCell 150, Thermo Electron 
Corporation) with 5% CO2 and 5% O2 at 37°C in RPMI 1640 containing 10% FBS, L-glutamine 
(0.292 mg/ml), penicillin (100 units/ml), and streptomycin (100 units/ml). 
 
Patient-derived leukemia cells and non-malignant controls 
Cells from peripheral blood were obtained from the Human Tissue Repository at the University 
of New Mexico Comprehensive Cancer Center (UNMCCC). All procedures were reviewed and 
approved by the Institutional Scientific Review Committee and Institutional Review Board (IRB). 
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Blood samples were obtained from adult AML patients (n=3) and from healthy volunteers (n=3). 
Mononuclear cells were isolated using Ficoll-Paque Plus (GE Healthcare). 
 
Synthetic peptides 
The peptides used in this study were synthesized by Polypeptide Laboratories under Good 
Manufacturing Practice (GMP) conditions, purified by high-performance liquid chromatography, 
and lyophilized. Reconstituted material was stable and maintained its potency through 
preparation and infusion. BMTP-78 is a synthetic peptidomimetic composed of the GRP78-
binding motif WIFPWIQL fused to the pro-apoptotic enantiomer D(KLAKLAK)2 through a Gly-Gly 
linker. 
 
Flow cytometry of cell lines 
One hundred thousand cells were blocked in phosphate-buffered saline (PBS) containing 10 
µg/ml human IgGs (Sigma) for 30 min on ice. Cells were successively incubated with goat anti-
GRP78 antibody (Santa Cruz, Clone C-20 or N-20) in labeling buffer [PBS containing 0.2% 
bovine serum albumin (BSA), 0.1% sodium azide (NaN3), and 5% heat-inactivated donkey 
serum] on ice for 1 h, washed with washing buffer (PBS containing 0.2% BSA and 0.1% NaN3) 
and incubated with a phycoerythrin (PE)-conjugated anti-goat antibody in labeling buffer for 30 
min. After additional rinsing in washing buffer, cells were resuspended in PBS containing 0.2% 
BSA and analyzed by flow cytometry (BD FACS Canto II). 
 
Flow cytometry of primary cells 
Mononuclear cells were isolated from peripheral blood with Ficoll-Plaque PLUS (GE Heathcare) 
and blocked in human IgGs as described above. The mouse monoclonal anti-GRP78 (clone 
[10c3], Abcam) and control isotype antibodies were conjugated to PE with the Lightning-Link R-
Phycoerythrin kit (Innova Biosciences). Cells were double-stained with anti-CD33 (conjugated to 
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PercP-Cy5.5) and anti-CD34 (conjugated to allophycocyanin, APC) antibodies (both 
eBioscience) for 1 h in the dark and on ice. Cells were analyzed with a BD Accuri C6 flow 
cytometer. Data were processed with FlowJo software package (V.10.0.8, FlowJo LLC). 
 
Cell viability and apoptosis assays 
For the viability assays, cells were seeded in 96-well plates (2x104 cells/well) in complete 
medium, and incubated overnight at 37°C with increasing concentrations of either BMTP-78 or 
an admixture of WIFPWIQL and D(KLAKLAK)2 at equimolar concentrations (negative control). 
Viability was determined by measuring the cytoplasmic lactate dehydrogenase (LDH) enzymatic 
activity with DHL™ Cell Viability & Proliferation Assay Kit (AnaSpec). For the apoptosis assays, 
OCI-AML cells were seeded in 6-well plates (2 x 105 cells/well), and incubated overnight at 37°C 
with 20 µM of either BMTP-78 or the control admixture, followed by staining with FITC-
conjugated annexin V and propidium iodide (PI, Sigma), and flow cytometry with a BD FACS 
Canto II. 
 
Statistical analysis 
All data are reported as the average mean ± standard error of the mean (S.E.M.). Student's t-test 
(unpaired) was used to determine statistical significance. P-values are represented as follows: * 
P<0.05 or ** P< 0.01. 
 
BMTP-78 toxicology in rodents 
Two studies were conducted with BMTP-78 in CD-1 female mice and Sprague Dawley® male 
rats at the UTMDACC Michale E. Keeling Center for Comparative Medicine and Research 
(Bastrop, Texas). The preliminary 5-day range-finding study consisted of 6 groups of 5 CD-1 
mice that received a single intravenous (i.v.) or subcutaneous (s.c.) dose of BMTP-78 (30, 100, 
or 200 mg/kg). A 14-day single-dose range-finding study was performed in Sprague Dawley® 
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rats. This study was designed as 5-day single dose (s.c.) followed by a 9-day recovery period, 
and consisted of 4 groups of 5 rats (5, 15, 50 or 150 mg/kg). In both studies, the control group 
was treated with vehicle alone. All animals were observed prior to dose initiation, and on days 1, 
5, 14, 28. Daily observations for signs of toxicity and body weights were recorded. At 
termination, animals were sacrificed and subjected to complete necropsy with histological 
evaluation of select tissues. Number of animals, doses and schedule for these studies are 
shown in Supplementary Table 1. 
 
BMTP-78 study in nonhuman primates 
Five GLP toxicology studies were conducted in cynomolgus monkeys (Macaca fascicularis) and 
rhesus monkeys (Macaca mulatta), at the UTMDACC Michale E. Keeling Center for 
Comparative Medicine and Research (Bastrop, Texas). Initial average animal weight was 5-9 kg; 
all animals were initially healthy with no history of chronic illness or injury. BMTP-78 was 
administered as a single infusion or multiple doses through a peripheral venous catheter. 
Number of animals, doses and schedules are shown in Table 1. Over the course of the study, 
the animals were observed twice daily for clinical signs of toxicity, including observations at 1 
and 2 h post-infusion on the days of BMTP-78 administration. Body weights were measured 
weekly, and blood and urine were collected for clinicopathological analysis. At the time of 
sacrifice, all monkeys were subjected to full necropsy, with tissues collected and processed for 
histopathological evaluation. Tissues were fixed in 10% neutral-buffered formalin, processed 
and embedded in paraffin, sectioned at 4-5 µm, and stained with hematoxylin and eosin (H&E). 
Eyes were fixed in Davidson’s solution (30 ml of 95% ethyl alcohol, 20 ml of 10% neutral 
buffered formalin, 10 ml glacial acetic acid, 30 ml ofd water), prior to processing and paraffin 
embedding. All GLP studies (rodents and primates) were registered with the FDA. 
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Results 
Expression of the surface-associated GRP78 in peripheral blood cells of AML patients 
To evaluate GRP78 as a potential target in leukemia, we analyzed its expression on the 
membrane of patient-derived cells via flow cytometry. The amount of surface-associated GRP78 
on peripheral blood cells was markedly increased in all AML samples (46.6 ± 3.9%) in 
comparison with normal healthy donors (3.6 ± 1.0%) (Fig. 1A). To investigate the tumor cell 
populations expressing GRP78, we used CD33 and CD34 in double-staining with an anti-
GRP78 antibody. CD33 is a specific myeloid receptor expressed in leukemic blasts and stem 
cells in AML,17, 18 and CD34 is a marker of immature leukemic cells and leukemic stem cells.19, 20 
In patients with AML, 26.6 ± 3.3% of the peripheral blood cells positive for CD33 were also 
positive for GRP78 (Fig. 1B). In healthy donors, the percentage of CD33+/GRP78+ cells was as 
low as 1.4 ± 0.4%. AML patients showed elevated numbers of CD34+ cells, which were 
specifically co-stained for GRP78 (37.3 ± 9.4%; compare with healthy donors, 1.4 ± 0.6%) (Fig. 
1C). Given the presence of GRP78 on the surface of leukemia cells from patients, we evaluated 
its expression in leukemia cell lines, including OCI-AML3 cells derived from the primary blast of 
an AML patient,21 and K562 and KBM-7 cells from patients with CML. All cells showed specific 
staining for surface GRP78 (Fig. 1D). These results show that GRP78 is expressed on the 
surface of human primary AML cells and leukemia cell lines, confirming previous studies where 
overexpression of unfolded protein response genes, including GRP78, was reported in AML 
patients.22 
 
BMTP-78 reduces the viability of human leukemia and lymphoma cells 
We have previously demonstrated that BMTP-78 selectively kills breast and prostate cancer 
cells, reducing both primary tumor growth and secondary spreading to the lungs and bones in 
mouse models.7 Here, we tested whether GRP78 could serve as a target for BMTP-78 in a 
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panel of human leukemia and lymphoma cell lines. All the cell lines tested were highly sensitive 
to BMTP-78: markedly reduced cell viability was observed at low molar concentrations, and, in 
most cases, the maximum cytotoxic effect was reached at ≤ 10 µM (Fig. 2). No detectable effect 
was observed with the control, which consisted of an equimolar admixture of WIFPWIQL and 
D(KLAKLAK)2. The effect of BMTP-78 on cell viability was also evaluated in primary cells from 
patients with AML. Three specimens of peripheral blood with 65-78% blasts were incubated with 
increasing molar concentrations of BMTP-78 or control peptides (Fig. 3). Notably, higher molar 
concentrations of BMTP-78 were necessary to decrease cell viability in primary human leukemia 
cells compared to the above-described cell lines: a complete loss of cell viability was observed 
at 10-30 μM. The negative control admixture had no detectable effects. Collectively, these 
results demonstrate the efficacy of BMTP-78 in reducing cell viability of established leukemia 
and lymphoma cell lines as well as of peripheral blasts from AML patients. 
 
BMTP-78 induces apoptosis in human leukemia cells 
We next evaluated morphologic changes in OCI-AML3 cells incubated for 16 h with 20 µM of 
either BMTP-78 or the control admixture of WIFPWIQL plus D(KLAKLAK)2. On microscopic 
analysis, cells treated with the control peptides showed a regular morphology, as opposed to 
cells treated with BMTP-78, which appeared “shrunken” and fragmented into characteristic 
apoptotic bodies (Fig. 4). The double positivity for annexin V and PI in > 70% of BMTP-78-
treated cells confirmed the microscopic assessments. In contrast, cells treated with the control 
admixture exhibited only background levels of cell death (~5%). We concluded that BMTP-78 
induces apoptosis in leukemia cells by specifically targeting cell surface-associated GRP78. 
 
Toxicology studies with BMTP-78 in rodents 
An initial dose range-finding study of BMTP-78 was performed in female CD-1 mice (n=5 
animals per group) dosed at 30, 100 and 200 mg/kg (i.v. or s.c.). Two control groups were 
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injected i.v. or s.c. with vehicle only (PBS). Similar signs of toxicity were noted in all treatment 
groups regardless of the administration route. Affected organs/tissues were: injection sites, 
lymphoid tissues, lungs, kidneys, and gastrointestinal tract. The lesions were characterized as 
degenerative, regenerative and/or inflammatory in nature. In most cases, renal and/or immune 
failure was considered as the cause of death after BMTP-78 administration. Body weights 
decreased in all mice treated with BMTP-78 (Supplementary Table 1). All mice in control groups 
appeared normal during the study. 
Successively, we performed a 5-day single dose followed by a 9-day recovery period in 
Sprague Dawley® male rats (n=5 animals per group) administered s.c. with BMTP-78 at 5, 15, 
50 and 150 mg/kg. In each group, 2 animals were sacrificed at day 5, and 3 at day 14. The 
incidence and severity of BMTP-78-related lesions occurred in a dose-dependent manner, and 
were more severe in the two high-dose groups (50 and 150 mg/kg), where all animals were dead 
or moribund at day 3. The 15 mg/kg dose appeared to be the midpoint of BMTP-78-related 
toxicity: 3 out of 5 animals were found dead by day 3. All animals in the 5 mg/kg treatment group 
survived to study termination with minimal lesions. Body weights in the high-dose groups (50 
and 150 mg/kg) were lower compared to the low-dose (5 mg/kg) and vehicle groups. Most 
affected were the kidneys, but alterations were also seen in the spleen, lymph nodes, and at 
injection sites. Kidney lesions were generally degenerative/necrotic in nature in the high-dose 
groups and regenerative in the low-dose groups. Renal failure was considered a cause of 
spontaneous death in these rats. Given the promising toxicology profile of BMTP-78 at low 
doses observed in rodents, we used these results to enable a dose-range selection for 
subsequent studies in nonhuman primates. 
 
Toxicology studies with BMTP-78 in nonhuman primates 
Within the class of D(KLAKLAK)2-containing compounds, we have previously evaluated GLP 
toxicities of agents against obesity (adipotide23, 24) and cancer (BMTP-1125, 26). We reported that 
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these BMTP-78-like compounds induce reversible renal toxicity and no adverse side effects in 
monkeys.24, 26 Inspired by these findings and by the above-described efficacy in vitro and in 
animal models, we evaluated BMTP-78 toxicology profiles in nonhuman primates. Five studies 
were designed, including single and multiple dose regimens, along with dose-range 
determination and repeated infusion for the assessment of BMTP-78 safety (Table 1). 
Preliminarily, a dose-escalating study (study #1) was performed in cynomolgus monkeys 
(n=3) serially dosed with BMTP-78 at 0.3, 3, 100 and 200 mg/kg via s.c. administration every 3 
days for 2 weeks. The study was terminated after the administration of 100 mg/kg dose due 
BMTP-78-related toxicity at the injection site and in the kidneys of all monkeys. In the 
subsequent study (study #2), cynomolgus monkeys (n=3) were scheduled to receive weekly i.v. 
doses (n=4) of BMTP-78 at 3 mg/kg. Two animals had complications and were euthanized after 
receiving a single dose of BMTP-78; one received all doses, but presented with necrotizing and 
inflammatory lesions at the i.v. injection site. Kidney lesions (cortical tubular necrosis) were also 
observed in one of the monkeys after a single dose. A substantially lower dose (0.75 mg/kg) of 
BMTP-78 was administered to cynomolgus monkeys (n=2) (study #3) and no adverse effects 
were detected. 
A second dose-ranging study (1-9 mg/kg) in rhesus monkeys (study #4) included 4 animals 
that were scheduled to receive 4 weekly i.v. doses of BMTP-78. The animal that received the 
highest dose (9 mg/kg) completed only 2 infusions and was euthanized shortly after the second 
week of treatment; the necropsy revealed a cardiac lesion not seen in the previous GLP 
toxicology studies. The lesion was present in the myocardium of the intraventricular septum and 
was degenerative and fibrotic. Although the animals that received the low (1 mg/ kg), mid-low (3 
mg/kg) and mid-high (6 mg/kg) doses completed the 4 weeks of treatment, kidney toxicity was 
observed in the animals treated with 3 and 6 mg/kg of BMTP-78, including tubular 
necrosis/degeneration and/or regeneration. Few necrotic foci were observed in the mid-low dose 
(3 mg/kg), minimal necrotic changes in the mid-high dose (6 mg/kg) and mild necrotic changes 
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in the high dose (9 mg/kg) animal. Similar to the monkeys in study #2, lesions were also 
observed at the injection site of the monkeys in the mid-low and mid-high doses. A description of 
protocols and the summary of results are presented in Table 1. 
Finally, we tested BMTP-78 safety in a large cohort of female rhesus monkeys (n=20), with 
4 i.v. infusions over a 22-day period, followed by a 29-day recovery period (study #5, 
Supplementary Table 2). The 20 animals were randomized in one control group (45% saline) 
and low (3 mg/kg) to high (30 mg/kg) dose groups. Each monkey was scheduled to receive 
BMTP-78 as a 2-h infusion once weekly. Two animals in the high dose group (30 mg/kg) 
presented with fatal cardiac arrhythmias shortly after the initial injection. A third animal received 
a single dose of 15 mg/kg and also developed heart arrhythmia with irreversible cardiac arrest. 
Two additional animals receiving the mid-high dose (9 mg/kg) of BMTP-78 developed fatal 
arrhythmias, one after the first infusion and one after the third. The other animals in the group 
developed tachycardia during all 4 infusions. At the low dose (3 mg/kg), all 5 animals displayed 
sinus tachycardia after the fourth infusion. In contrast with higher doses, this sinus tachycardia 
did not convert to life-threatening ventricular arrhythmias. Due to the severe heart toxicity and 
the risk of fatal cardiac arrhythmias, the GLP toxicology studies were terminated early in an 
abrogated fashion, as required by the FDA. 
Altogether these studies led to the conclusion that, despite the promising anti-tumor effect of 
BMTP-78 in vitro and in preclinical cancer models, the current formulation is not suitable to be 
pursued for cancer treatment because of unexpected cardiac toxicity resulting in unanticipated 
morbidity and mortality. 
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Discussion 
The expression of stress-related proteins has been reported in many solid tumors as a response 
to unfavorable microenvironment conditions such as hypoxia and glucose deprivation.1, 27 In the 
bone marrow, low oxygen levels are observed in the endosteal area where hematopoietic stem 
cells are maintained in a quiescent niche while maintaining a pluripotent state.28 This 
phenomenon results from the activation of hypoxia inducible factor 1 (HIF-1) and other targets 
including VEGFA, CXCR4 and the Cripto/GRP78 complex.14, 29, 30 The levels of surface-
associated GRP78 have been used to distinguish two populations of hematopoietic stem cells: 
one, characterized as GRP78+/CD34-, seems to be a myeloid-biased lineage with slow engraft 
reconstitution ability, while the other (GRP78-/CD34-) tends to generate a compromised 
lymphoid lineage.31 In hematopoietic malignancies, disease progression has been linked to vast 
expansion of hypoxic areas within the bone marrow and overexpression of the GRP78-binding 
partner Cripto32 to form a supramolecular complex on the cell surface. Consistent with these 
findings, elevated expression of surface-associated GRP78 has been described in several tumor 
types,5-10, 33 most of which are characterized by a hypoxic microenvironment. The mechanism of 
GRP78 relocation from the ER to the plasma membrane seems to be dependent on hypoxia and 
nutrient deprivation;34 therefore, its association with co-receptors that trigger cell proliferation 
and prevent apoptosis is considered a hallmark of cancer cells. 
Here we report the expression of surface-associated GRP78 in cells from patients with AML, 
as well as in different human leukemia cell lines. Our results explore whether GRP78 would be 
an accessible molecular target for drug delivery, by extending previous results in which 
expression of surface-associated GRP78 was shown in B-cell ALL11 and CLL.35 To address this 
hypothesis, we tested the GRP78-targeted peptidomimetic BMTP-78 in vitro in a panel of human 
leukemia and lymphoma cell lines and primary cells from patients with AML. BMTP-78 reduced 
cell viability in all conditions tested and at a lower concentration (< 10 µM) than BMTP-11 (60-80 
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µM36), an IL11-Rα-targeting drug that has been recently evaluated in a first-in-man clinical trial.26 
BMTP-78 treatment resulted in apoptosis, confirming that this compound, like BMTP-1125, 26 and 
adipotide,23, 24 induces cell death by a ligand-specific pathway. 
Despite the promising anti-tumor effects of BMTP-78 in vitro and in preclinical tumor 
models,5, 7 and a favorable toxicity profile in rodents at low doses, its current formulation has 
shown unexpected side effects in primates, thereby deeming this drug candidate unsuitable for 
clinical testing. Of note, BMTP-78-related toxicity was not observed in therapeutic studies with 
tumor-bearing mice, probably due the dose used (15 mg/kg).6, 8 Toxic effects in mice were 
observed at 30 mg/kg and above, although in rats 15 mg/kg was already considered a midpoint 
for the drug test. Interestingly, no cardiac abnormalities were observed in any toxicology studies 
performed in rodents. The D(KLAKLAK)2 pro-apoptotic moiety has been extensively used by us5, 
7, 16, 37 and others38-41 to develop ligand-directed therapeutics, and two of our most advanced 
D(KLAKLAK)2-based formulations have been successfully granted safe-to-proceed and 
translated into FDA clinical trials.24, 26 These observations allow excluding a causative 
involvement of D(KLAKLAK)2 in the observed adverse events. We speculate that the biochemical 
features of WIFPWIQL, e.g. its high content in hydrophobic residues (Ile, Phe, Pro, Leu, Trp) 
might contribute to its insolubility and tissue-specific toxicity. Of note, WIFPWIQL was originally 
identified by an in silico analysis,15 as opposed to other targeting peptides that our group has 
selected via in vivo screenings and that have been exploited in formulations compatible with 
preclinical and/or clinical studies. Further investigation is needed to assess a potential toxicity 
profile of WIFPWIQL. Meanwhile, we have recently identified a new GRP78-targeting motif from 
an in vivo phage display selection in a patient-derived xenograft model of prostate cancer.10, 42, 43 
This peptide, SNTRVAP, might therefore resolve the toxicity issues of the current BMTP-78 
formulation. 
In the present work, we describe and confirm the presence of membrane-associated GRP78 
in human leukemia cells and investigate the targeting of GRP78 with BMTP-78. We conclude 
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that the first generation of BMTP-78 should no longer be pursued in clinical testing because of 
its unacceptable toxicity profile in nonhuman primates. However, several aspects merit further 
comment. First, BMTP-78 will likely still be useful as a molecular imaging probe, because the 
molar doses used would be several orders of magnitude lower. As such, a study of WIFPWIQL 
conjugated to 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) for PET imaging 
is currently under planning with the lead labeled compound already synthesized in GMP grade 
(unpublished observations). Moreover, as mentioned, a next-generation GRP78 ligand has been 
selected and validated for therapeutic applications.10, 42 Collectively, this GLP-toxicology study 
serves as a cautionary note in which species-specific toxicity must be taken into account during 
preclinical drug development. The fact that the toxicity profile of BMTP-78 in rodents was 
essentially indistinguishable from adipotide24 and BMTP-11,26 but the nonhuman primate study 
showed unexpected cardiac toxicity in the form of lethal heart arrhythmias, is quite remarkable 
and should give pause to drug development efforts. Nevertheless, despite the toxicity of BMTP-
78 described herein, the accessibility of GRP78 and its potential as a target remain a path to be 
pursued for the treatment of hematopoietic malignancies. 
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Figure Legends 
Figure 1. Detection of cell surface-associated GRP78 in leukemia. (A) The expression of 
GRP78 was studied in mononuclear cells isolated from peripheral blood of patients with AML 
compared with healthy donors. Ficoll-purified cells were stained with PE-conjugated anti-GRP78 
or control isotype antibody. Cells were double-stained with PE-conjugated anti-GRP78 plus (B) 
PercP-Cy5.5-conjugated anti-human CD33 or (C) APC-conjugated anti-human CD34 antibody. 
(D) Leukemia cell lines (OCI-AML3, K562 and KBM-7) were stained with PE-conjugated anti-
GRP78 or control isotype antibody and analyzed by flow cytometry. Non-stained cells were used 
as a negative control. The percentage of double-stained cells is represented. * P < 0.05; ** P < 
0.01. 
 
Figure 2. Effect of BMTP-78 on cell viability. A panel of human leukemia and lymphoma cell 
lines was treated with increasing concentrations of BMTP-78 or control peptides. Cell viability 
was measured by LDH activity. Results represent the average of three independent 
experiments. 
 
Figure 3. Drug activity of BMTP-78 in primary human leukemia cells. Peripheral blood cells 
purified from three AML patients were incubated with increasing concentrations of BMTP-78 or 
control peptides. Cell viability was measured via LDH enzymatic activity. 
 
Figure 4. Effect of BMTP-78 on cell death by apoptosis. OCI-AML3 cells were treated for 16 h 
with BMTP-78 or control peptides (20 µM), followed by staining with Annexin V/PI to detect the 
percentage of apoptotic cells by flow cytometry. Untreated OCI-AML3 cells served to determine 
background levels of cell death under the same experimental conditions. 
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Table 1. Toxicology studies of BMTP-78 in nonhuman primates 
Study Protocol Animals Sex Number 
of 
animals 
Doses schedule Dose  
(# animals) 
Adverse effects and  
necropsy results 
(# affected animals) 
1 Multiple dose range study 
s.c. injections of BMTP-78  
Macaca 
fascicularis 
M 3 1 dose every 3 
days for 2 weeks 
s.c. 
0.3, 3, 30, 100, 200 
mg/kg (3) 
Kidney toxicity (after 100 mg/kg 
dose) 
Lesions at s.c. injection site 
2 Multiple dose i.v. infusion Macaca 
fascicularis 
M 3 4 weekly i.v. 
 
3 mg/kg (3) Necrotizing and inflammatory 
lesions at i.v. injection site (3) 
Kidney lesions (1) 
3 Single dose i.v. infusion  Macaca 
fascicularis 
M 2 Single infusion 0.75 mg/kg (2) None  
4 Dose range study of weekly 
infusions of BMTP-78 
Macaca 
mulatta 
M 4 4 weekly i.v. Low: 1 mg/kg (1) 
Mid-low: 3 mg/kg (1) 
Mid-high: 6 mg/kg (1) 
High: 9 mg/kg (1) 
Dose-dependent kidney toxicity 
(3 at ≥ 3 mg/kg doses) 
Lesions at i.v. injection site (3 at ≥ 3 
mg/kg doses) 
Heart toxicity (1 at 9 mg/kg doses) 
5 22-day repeated infusion of 
BMTP-78 
Macaca 
mulatta 
F 20 4 infusions every 
5 days i.v. 
followed by 29-
day recovery 
Control: vehicle (4) 
Low: 3 mg/kg (5) 
Mid-low: 9 mg/kg (8) 
Mid-high: 15 mg/kg (1) 
High: 30 mg/kg (2) 
Heart toxicity (15 at ≥ 3 mg/kg 
doses), lethal at mid-high doses  (5 at 
≥ 9 mg/kg doses) 
